ENVALITH
ネクセラファーマ株式会社 logo

Nxera Pharma Co., Ltd.

4565・Prime Market・Pharmaceuticals

Official website
ネクセラファーマ株式会社 logo
Nxera Pharma Co., Ltd.4565
Reference Indicators

Market Cap

827¥100M

P/E (Forecast)

—

P/B

1.4x

Dividend Yield (Forecast)

0.00%

ROE

-20.5%

EV/EBITDA

—
Financial Summary
Unit: ¥M
Item
2021Dec 2021
2022Dec 2022
2023Dec 2023
2024Dec 2024
2025Dec 2025
Net Sales
17,71215,56912,76628,83529,615
Cost of Sales
9339263,1027,6168,198
Gross Profit
16,77914,6439,66421,21921,418
SG&A Expenses
3,9404,3779,96516,01515,225
Operating Income
3,7753,436-9,526-5,423-8,462
Pre-tax Income
4331,078-10,680-4,662-14,950
Income Taxes
-584696-3,487176-2,420
Net Income
1,017382-7,193-4,838-12,530
EBITDA
5,0534,781-7,048-1,439-4,096
Gross Margin
94.7%94.1%75.7%73.6%72.3%
Operating Margin
21.3%22.1%-74.6%-18.8%-28.6%
ROA
1.0%0.4%-4.6%-3.2%-9.3%
ROE
1.8%0.7%-10.8%-7.1%-20.5%